---
title: "BUZZ-Vir Biotech drops after $150 mln stock sale"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277032067.md"
datetime: "2026-02-26T11:37:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277032067.md)
  - [en](https://longbridge.com/en/news/277032067.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277032067.md)
---

# BUZZ-Vir Biotech drops after $150 mln stock sale

Vir Biotechnology’s (VIR.O) shares down 10% premarket at $9 after $150 mln follow-on priced San Francisco, California-based firm late Weds announced ~17.6 mln shares at $8.50, a 15% discount to last sale VIR shares finished up ~5% at $10 on Weds following 28% gain on Tues after co posted Q4 rev beat and said it’s collaborating to develop its prostate cancer experimental drug with Japan’s Astellas (4503.T) After the bell Tues, co announced $200 mln stock offering It intends to use net offering proceeds to fund its portion of global clinical development costs, and potential portion of commercial launch costs for the drug, VIR-5500, under the Astellas agreement, among other purposes, per the offering prospectus

Goldman Sachs, Leerink, Evercore and Barclays joint bookrunners

Co has ~139.5 mln shares outstanding

Through Weds, stock up 66% YTD

All 10 analysts covering VIR are bullish and their median PT is $18, per LSEG data (Lance Tupper is a Reuters market analyst. The views expressed are his own)

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VIR.US](https://longbridge.com/en/quote/VIR.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer | VIR Stock News](https://longbridge.com/en/news/282996089.md)
- [Vir Biotechnology announces annual shareholder meeting](https://longbridge.com/en/news/283003484.md)
- [BUZZ-Cancer biotech Adlai Nortye jumps after $150 mln equity financing](https://longbridge.com/en/news/282996483.md)
- [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)